Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer

首页> 外文期刊>Progress in Artificial Intelligence >Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer

【24h】

Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer

机译：抑制骨桥蛋白克服了EGFR-突变体非小细胞肺癌中对AFATINIB的抗性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: We aimed to explore a novel therapeutic strategy to conquer acquired resistance to second generation EGFR-TKI afatinib in EGFR-mutant NSCLC.

机译：背景：我们旨在探索征服EGFR-突变NSCLC中的第二代EGFR-TKI AFATINIB的诱因诱发新的治疗策略。

著录项

来源
《Progress in Artificial Intelligence》 |2020年第2期|共9页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类计算技术、计算机技术;
关键词
Afatinib; osteopontin (OPN); epithelial-mesenchymal transition (EMT); NSCLC;

机译：AFATINIB;骨桥蛋白（OPN）;上皮 - 间充质转换（EMT）;NSCLC;

相似文献

外文文献
中文文献
专利

1. Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer [J] . Progress in Artificial Intelligence . 2020,第2期

机译：抑制骨桥蛋白克服了EGFR-突变体非小细胞肺癌中对AFATINIB的抗性
2. Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors [J] . Landi Lorenza, Tiseo Marcello, Chiari Rita, Clinical lung cancer . 2014,第6期

机译：EGFR-突变型肺癌对可逆EGFR酪氨酸激酶抑制剂具有耐药性的EGFR突变型肺癌患者中EGFR-HER2双重抑制剂Afatinib的活性
3. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib [J] . Li Yiting, Zang Hongjing, Qian Guoqing, Cancer: A Journal of the American Cancer Society . 2020,第6期

机译：ERK抑制有效地克服了表皮生长因子受体 - 突变体非小细胞肺癌细胞对Osimertinib的抗性
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer [O] . Shunichi Nishima, Akihiko Miyanaga, Sho Saito, 2021

机译：在患有EGFR-突变体非小细胞肺癌的患者中在Osimertinib诱导的间质肺病中成功治疗Afatinib
7. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib [O] . Horn, Leora, Gettinger, Scott, Camidge, D. Ross, 2017

机译：EGFR突变阳性的非小细胞肺癌并获得了对吉非替尼或厄洛替尼耐药的患者，在阿法替尼治疗进展后继续使用阿法替尼加西妥昔单抗治疗
8. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers. [R] . Engelman, J., Sequist, L. 2016

机译：缺乏BIm表达作为EGFR-突变和aLK阳性肺癌中靶向疗法的内在和获得性抗性的机制。

Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅